BIODESIX INC 8-K

What Happened

• Biodesix, Inc. (BDSX) filed an 8-K reporting the results of its 2026 annual meeting of stockholders held May 19, 2026 (record date March 23, 2026; 10,107,219 shares outstanding).
• Stockholders elected two Class III directors — Jean Franchi and Hany Massarany — approved, on a non‑binding advisory basis, the compensation of the named executive officers and the frequency (one year) of future advisory votes on compensation, and ratified KPMG LLP as the company’s independent registered public accounting firm for 2026.

Key Details

• Director elections: Jean Franchi — For 6,191,974; Abstentions 721,832; Broker non‑votes 1,784,659. Hany Massarany — For 6,847,586; Abstentions 66,220; Broker non‑votes 1,784,659.
• Say-on-pay (non‑binding): Approved — For 6,618,755; Against 283,474; Abstentions 11,577; Broker non‑votes 1,784,659.
• Say-on-frequency (non‑binding): One year preferred — One Year 6,114,363; Two Years 4,393; Three Years 777,394; Abstentions 17,656; Broker non‑votes 1,784,659.
• Auditor ratification: KPMG LLP ratified — For 8,695,977; Against 59; Abstentions 2,429.

Why It Matters

• Board continuity: Election of the two Class III directors keeps Biodesix’s current board composition in place through the 2029 annual meeting, supporting continuity of governance and strategy execution.
• Executive compensation and governance: Stockholders approved the company’s executive pay on an advisory basis and indicated an annual (one‑year) frequency for future say‑on‑pay votes; these votes are advisory (non‑binding) but signal shareholder sentiment on pay practices.
• Audit continuity: Ratification of KPMG ensures the company’s independent auditor for 2026, which is relevant for financial reporting and investor confidence.